A new ranibizumab injection offers hope for patients with wet age-related macular degeneration, according to a presentation at Hawaiian Eye 2022. It was great to catch up with Dr Carl Regillo (Thomas Jefferson University, Philadelphia, PA, USA), who talked to us about the ranibizumab injection and its advantages over anti-vascular endothelial growth factor injections.
The abstract entitled Update on Emerging Wet AMD Therapies was presented at Hawaiian Eye 2022, 15–21 January 2022.
- Could you tell us a little about the ranibizumab injection and its advantages over anti-vascular endothelial growth factor injections? (00:15)
- What is the likely role of faricimab in the treatment paradigm for wet age-related macular degeneration? (02:15)
Speaker Disclosure: Carl Regillo has received speakers’ fees from Genentech, Allergan, Annexon, Novartis, Apellis, Iveric, NGM, Adverum, Regenxbio, Regeneron, Opthea, Thea.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed in coverage of Hawaiian Eye 2022.
Share this Video
Related Videos In Macular Degeneration
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Rahul Khurana, AAO 2022: Loss to follow-up in patients with nAMD treated with anti-VEGF therapy in the US
Dr Rahul Khurana (Northern California Retina Vitreous Associates, Mountain View, CA, USA) took part in a retrospective cohort study investigating the incidence of loss to follow-up after anti–vascular endothelial growth factor (VEGF) injections among patients with neovascular age-related macular degeneration. In this interview, he discusses with touchOPHTHALMOLOGY the design and findings of this study as […]
Francesco Bandello, EURETINA 2022: The Relationship Between OCTA and FA/ICGA in AMD Part 1
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) talks us through the advantages of optical coherence tomography angiography (OCTA) over conventional dye angiography in age-related macular degeneration (AMD) and a study investigating the relationship between OCTA and fluorescein angiography/indocyanine green angiography in AMD. ‘Morphological and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!